Main Article Content

Abstract

The main problems to humans include the infection caused in the respiratory tract and urinary tract, namely respiratory tract infection (RTI) and urinary tract infection (UTI). Cefpodoxime Proxetil drug is available in the market that has a problem with drug release profile and flows property. To overcome this problem, the compacted powder form made into a micro-ionized form for its better flow property and drug release by using a direct compression technique. The study was based on the aim to evaluate and formulate oro-dispersible tablets as an effective approach via orally for the treatment of RTI & UTI prepared by direct compression technique. FTIR and DSC showed no incompatibility between drugs and excipients. The pure drug Cefpodoxime Proxetil and the excipients were blended using an octagonal blender. The Pre-formulation study was performed for this blend and pure drug. Further, the blend was made compressed into a tablet by direct compression technique. Two factorial design was implemented. Prepared tablets were evaluated for drug content, hardness, thickness, uniformity in the weight, friability, disintegration test, dispersion time, in-vitro studies, release kinetics, and also stability studies. The optimized formulation A6 found to have good flow property. The evaluation results of optimized formula A6 showed 99.60% drug content, 390mg average weight, 0.91% weight uniformity, 3.80 kg/cm2 hardness, 0.67%, friability, 23.70sec, disintegration time, 16 sec dispersion time and 95.5% drug release than the other formulation batch. The current study showed that the optimized formula A6 exhibited good disintegration time, drug release, and friability than marketed product X and other batches.

Keywords

Oro-dispersible tablets (ODTs) Super disintegrants Cefpodoxime Proxetil RTI UTI

Article Details

How to Cite
Akshay Kumar S, Gowda D V, Sharadha M, & Famna Roohi N K. (2020). Formulation and evaluation of third-generation Cefpodoxime proxetil as an Oro-dispersible tablets for treating infections. International Journal of Research in Pharmaceutical Sciences, 11(1), 921-932. https://doi.org/10.26452/ijrps.v11i1.1916